Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ibuprofen  COVID-19 treatment studies for Ibuprofen  C19 studies: Ibuprofen  Ibuprofen   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -170% Improvement Relative Risk Mortality (b) 37% Oxygen therapy -45% Hospitalization -18% Severe case -85% c19early.com/ib Abu Esba et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
Abu Esba, 397 patient ibuprofen early treatment study: 170% higher mortality [p=0.35], 45% higher need for oxygen therapy [p=0.64], 18% higher hospitalization [p=0.64], and 85% higher severe cases [p=0.42] https://c19p.org/abuesba
copied to clipboard
Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study
Abu Esba et al., Infectious Diseases and Therapy, doi:10.1007/s40121-020-00363-w
2 Nov 2020    Source   PDF   Share   Tweet
Prospective study of 503 COVID-19 cases in Saudi Arabia, 40 using ibuprofen during infection, and 357 not using NSAIDs, showing no significant differences in outcomes. Results are subject to confounding by indication.
risk of death, 169.5% higher, RR 2.70, p = 0.35, treatment 40, control 357, adjusted per study, multivariable.
risk of death, 36.8% lower, HR 0.63, p = 0.68, treatment 40, control 357, Cox proportional hazards.
risk of oxygen therapy, 44.8% higher, RR 1.45, p = 0.64, treatment 40, control 357, adjusted per study, multivariable.
risk of hospitalization, 18.2% higher, RR 1.18, p = 0.64, treatment 40, control 357, adjusted per study, multivariable.
risk of severe case, 84.8% higher, RR 1.85, p = 0.42, treatment 40, control 357, adjusted per study, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.
Abu Esba et al., 2 Nov 2020, prospective, Saudi Arabia, peer-reviewed, 6 authors, study period 12 April, 2020 - 1 June, 2020.
Contact: abuesbala@ngha.med.sa.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIbuprofenAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit